Prem Watsa

The record

Prem Watsa took over Fairfax Financial Holdings in 1985 and built it from a small Canadian insurer into a global property-and-casualty holding company with roughly $32 billion in gross written premiums by 2023. Over 38 years, Fairfax’s book value per share has compounded at approximately 18.9% annually, with the stock price compounding at about 18.2% — a publicly reported, audited, regulated-company record, not a private claim.

The philosophy — Graham’s discipline plus Buffett’s structure

Watsa explicitly modeled Fairfax on Berkshire Hathaway, combining two ideas:

• Value investing rooted in Benjamin Graham — buy undervalued assets with a real margin of safety, and hold for the long term rather than trade around short-term price moves.
• Insurance float as investment capital. Like Berkshire, Fairfax collects insurance premiums long before claims come due; that pool of “float” becomes a low-cost source of capital Watsa invests for the long run — an ordinary insurance business turned into a compounding machine through disciplined capital allocation.
• Willingness to be sharply contrarian. Fairfax’s best-known trade was a large bet against the U.S. housing market via credit default swaps heading into the 2008 financial crisis, which generated roughly $3 billion in gains — a documented, publicly reported outcome, not an anecdote.

Why we rate this 9 / 10 — Trusted

• A verifiable, 38-year record at a publicly traded, audited holding company anyone can research through its own annual reports.
• Radical transparency. Watsa has published detailed annual shareholder letters explaining his reasoning for decades, in the same tradition as Buffett and Munger.
• A clean record and a business model — insurance float plus disciplined value investing — that is fully inspectable in Fairfax’s public financial statements.

Fair cautions

• Insurance-linked investing carries its own risks — underwriting losses, reserve adequacy, and catastrophe exposure all affect the float available to invest, separate from the investment returns themselves.
• Fairfax’s stock price has, at various points, traded at a discount to book value for extended periods — a reminder that a good long-term record doesn’t mean every year looks good.
• As always, be skeptical of anyone using the “Canadian Warren Buffett” label to sell an unrelated product.

Invest like Watsa: AI prompt

Watsa’s method combines Graham-style value screening with a check on the quality of the underlying insurance operations funding it. Paste this into any AI assistant with a company (insurance-linked or otherwise) you’re evaluating:

Act as a value investor following Prem Watsa's documented approach (Fairfax Financial):
Benjamin Graham-style margin-of-safety investing, funded by disciplined insurance
float where applicable. I will describe a company. Evaluate it as follows:

1. Margin of safety. Using conservative, verifiable assumptions, estimate intrinsic
   value and compare it to the current price. Is there a real discount, or does the
   price already assume optimistic outcomes?
2. If this is an insurance or float-generating business: is the underwriting
   disciplined (combined ratio consistently near or below 100 over a full cycle,
   reserves that have proven adequate over time), or is float being generated by
   underpricing risk to grow faster? Cheap float from bad underwriting is a liability,
   not an asset.
3. Contrarian check. Is this priced attractively specifically because the market is
   currently pessimistic about it for reasons that may not reflect the underlying
   long-term value? Name the specific pessimistic narrative and whether it's
   temporary or structural.
4. Capital allocation discipline. Does management have a demonstrated record of
   investing available capital (or float) rationally over a full cycle, including
   periods when it made more sense to hold cash or hedge than to invest aggressively?
5. Time horizon. Is this a multi-year holding thesis, consistent with how Watsa has
   historically held positions, or does it depend on a near-term catalyst?

Conclude with the specific evidence for or against a genuine margin of safety. This is
a research framework, not financial advice.

← Back to all reviews